» Articles » PMID: 38921029

The Neuromuscular Disorder Mediated by Extracellular Vesicles in Amyotrophic Lateral Sclerosis

Overview
Publisher MDPI
Specialty Molecular Biology
Date 2024 Jun 26
PMID 38921029
Authors
Affiliations
Soon will be listed here.
Abstract

Amyotrophic lateral sclerosis (ALS) represents a neurodegenerative disorder characterized by the progressive loss of both upper and lower motor neurons, resulting in muscular atrophy and eventual paralysis. While much research has concentrated on investigating the impact of major mutations associated with ALS on motor neurons and central nervous system (CNS) cells, recent studies have unveiled that ALS pathogenesis extends beyond CNS imbalances, encompassing dysregulation in other tissues such as skeletal muscle. Evidence from animal models and patients supports this broader perspective. Skeletal muscle, once considered solely as an effector organ, is now recognized as possessing significant secretory activity capable of influencing motor neuron survival. However, the precise cellular and molecular mechanisms underlying the detrimental effects observed in muscle and its associated structures in ALS remain poorly understood. Additionally, emerging data suggest that extracellular vesicles (EVs) may play a role in the establishment and function of the neuromuscular junction (NMJ) under both physiological and pathological conditions and in wasting and regeneration of skeletal muscles, particularly in neurodegenerative diseases like ALS. This review aims to explore the key findings about skeletal muscle involvement in ALS, shedding light on the potential underlying mechanisms and contributions of EVs and their possible application for the design of biosensors.

Citing Articles

Muscle-specific Bet1L knockdown induces neuromuscular denervation, motor neuron degeneration, and motor dysfunction in a rat model of familial ALS.

Eckardt A, Marble C, Fern B, Moritz H, Kotula C, Ke J Front Neurosci. 2025; 19:1527181.

PMID: 39896335 PMC: 11782205. DOI: 10.3389/fnins.2025.1527181.

References
1.
Iguchi Y, Eid L, Parent M, Soucy G, Bareil C, Riku Y . Exosome secretion is a key pathway for clearance of pathological TDP-43. Brain. 2016; 139(Pt 12):3187-3201. PMC: 5840881. DOI: 10.1093/brain/aww237. View

2.
Guo M, Wang J, Zhao Y, Feng Y, Han S, Dong Q . Microglial exosomes facilitate α-synuclein transmission in Parkinson's disease. Brain. 2020; 143(5):1476-1497. PMC: 7241957. DOI: 10.1093/brain/awaa090. View

3.
Condrat C, Thompson D, Barbu M, Bugnar O, Boboc A, Cretoiu D . miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells. 2020; 9(2). PMC: 7072450. DOI: 10.3390/cells9020276. View

4.
Dinkins M, Dasgupta S, Wang G, Zhu G, Bieberich E . Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging. 2014; 35(8):1792-800. PMC: 4035236. DOI: 10.1016/j.neurobiolaging.2014.02.012. View

5.
Dugger B, Dickson D . Pathology of Neurodegenerative Diseases. Cold Spring Harb Perspect Biol. 2017; 9(7). PMC: 5495060. DOI: 10.1101/cshperspect.a028035. View